Filtered By:
Specialty: Cancer & Oncology
Source: Clinical Lung Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Development of a dynamic motion platform with two independent drive systems for radiotherapy
CONCLUSIONS: A new dynamic platform for radiation therapy with two drive systems capable of three-axis motion was developed, and the positional accuracy of the drive axes was confirmed to be less than 0.2 mm.PMID:36951306 | DOI:10.1002/acm2.13971
Source: Clinical Lung Cancer - March 23, 2023 Category: Cancer & Oncology Authors: Masahide Saito Hideyuki Kawakami Toshihiro Suzuki Hidekazu Suzuki Koji Ueda Hikaru Nemoto Naoki Sano Hiroshi Onishi Source Type: research
Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data
CONCLUSION: Concordance between datasets was lower than anticipated and the HSD used could not straightforwardly replace current trial practices, nor directly identify protocol-defined CVS events. Further work is required to improve the quality of HSD and consider event definitions when designing clinical trials incorporating HSD.PMID:36933612 | DOI:10.1016/j.cct.2023.107162
Source: Clinical Lung Cancer - March 18, 2023 Category: Cancer & Oncology Authors: Archie Macnair Matthew Nankivell Macey L Murray Stuart D Rosen Sally Appleyard Matthew R Sydes Sylvia Forcat Andrew Welland Noel W Clarke Stephen Mangar Howard Kynaston Roger Kockelbergh Abdulla Al-Hasso John Deighan John Marshall Mahesh Parmar Ruth E Lan Source Type: research
Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma
CONCLUSION: For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.PMID:36585562 | DOI:10.1007/s12094-022-03034-z
Source: Clinical Lung Cancer - December 30, 2022 Category: Cancer & Oncology Authors: Orla A Houlihan Georgios Ntentas David J Cutter Patricia Daly Charles Gillham Orla McArdle Frances K Duane Source Type: research
Active screening for lung cancer increases smoking abstinence in Australia
CONCLUSIONS: This study provides the first data on smoking cessation rates in Australian lung cancer screenees and supports screening as a teachable moment. We identify several factors that identify smokers who may require more intensive smoking cessation interventions and could be used to develop effective smoking cessation as part of lung cancer screening, tailored to individual risk profiles.PMID:36437500 | DOI:10.1111/ajco.13879
Source: Clinical Lung Cancer - November 28, 2022 Category: Cancer & Oncology Authors: Henry M Marshall Mounavi Vemula Karen Hay Elizabeth McCaul Linda Passmore Ian A Yang Rayleen V Bowman Kwun M Fong Source Type: research
Poorly Differentiated Lung Cancer with Intracardiac Extension Causing Malignant Stroke in a Peritoneal Dialysis Patient: a Case Report
SN Compr Clin Med. 2022;4(1):255. doi: 10.1007/s42399-022-01331-w. Epub 2022 Nov 14.ABSTRACTCardiac involvement occurs in an almost one quarter of all the patients with lung cancer. Lymphatogenous spread is a more common route of tumor dissemination than the hematogenous spread. It was a retrospective case report. We hereby report a case of myocardial involvement by non-small cell lung cancer leading to an uncommon presentation of a malignant stroke and death in a peritoneal dialysis patient.PMID:36404986 | PMC:PMC9662106 | DOI:10.1007/s42399-022-01331-w
Source: Clinical Lung Cancer - November 21, 2022 Category: Cancer & Oncology Authors: Sahil Bagai Vipra Malik Pallavi Prasad Priyanka Singh Amit Sahu Dinesh Khullar Source Type: research
Neurovascular Manifestations of Iron-Deficient Anemia: Narrative Review and Practical Reflections through a Teaching Case
Conclusions: IDA is a common but treatable condition that, independently or synergically, may increase the risk of thrombotic events. The diagnostic and therapeutic approach has not yet been defined, and each case should be individually addressed in a pragmatic clinical road map.PMID:36294407 | DOI:10.3390/jcm11206088
Source: Clinical Lung Cancer - October 27, 2022 Category: Cancer & Oncology Authors: Marialuisa Zedde Giacomo Portaro Laura Ferri Francesco Cavallieri Manuela Napoli Claudio Moratti Fabrizio Piazza Franco Valzania Rosario Pascarella Source Type: research
The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations
CONCLUSIONS: Among Asians, immune checkpoint inhibitors were associated with an increased risk of major adverse cardiovascular events, particularly ischemic stroke and pulmonary embolism.PMID:36208180 | DOI:10.1093/jjco/hyac150
Source: Clinical Lung Cancer - October 8, 2022 Category: Cancer & Oncology Authors: Cho-Han Chiang Cho-Hung Chiang Kevin Sheng-Kai Ma Yuan Ping Hsia Yu-Wen Lee Han-Ru Wu Cho-Hsien Chiang Chun-Yu Peng James Cheng-Chung Wei Her-Shyong Shiah Cheng-Ming Peng Tomas G Neilan Source Type: research
Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis
CONCLUSION: Current clinical evidence supports the effectiveness of pharmacological intervention with beta-blockers, amiodarone, magnesium sulfate, or calcium-channel blockers to reduce the incidence of POAF after lung surgery in patients with lung cancer. In the absence of contraindications, prophylaxis with beta-blockers seems to be the most effective of the treatments studied.PMID:36136141 | DOI:10.1007/s00228-022-03383-2
Source: Clinical Lung Cancer - September 22, 2022 Category: Cancer & Oncology Authors: Xiaomei Wang Demei Zhang Yanxia Ren Jingjing Han Guangling Li Xueya Guo Source Type: research
Increased Carcinoembryonic Antigen (CEA) Level Is Highly Associated with Low Skeletal Muscle Mass in Asymptomatic Adults: A Population-Based Study
J Clin Med. 2022 Aug 26;11(17):5009. doi: 10.3390/jcm11175009.ABSTRACTWe investigated the relationship between high carcinoembryonic antigen (CEA) levels and low skeletal muscle mass (LMM) in asymptomatic adults in a population-based study. A total of 202,602 adults (mean age 41.7 years) without malignancy, stroke, cardiovascular disease, or chronic lung/liver disease were included. A high CEA level was defined as ≥5 ng/mL. Skeletal muscle mass index (SMI) was calculated based on appendicular muscle mass (kg)/height (m)2. Participants were classified into three groups based on SMI: "normal", "mild LMM", and "severe LMM."...
Source: Clinical Lung Cancer - September 9, 2022 Category: Cancer & Oncology Authors: Chul-Hyun Park Antonio Diaz Lizarraga Yong-Taek Lee Kyung-Jae Yoon Tae-Kyung Yoo Source Type: research
Short bevacizumab infusion as an effective and safe treatment for colorectal cancer
Mol Clin Oncol. 2022 Jul 27;17(3):139. doi: 10.3892/mco.2022.2572. eCollection 2022 Sep.ABSTRACTBevacizumab is a humanized monoclonal antibody that contains <10% murine protein. To prevent infusion-related hypersensitivity reactions (HSRs), the initial bevacizumab infusion is delivered for 90 min, the second for 60 min and subsequent doses for 30 min. Several previous studies have shown that short bevacizumab infusions are safe and do not result in severe HSRs in patients with colorectal, lung, ovarian and brain cancer. However, the efficacy of short bevacizumab infusions for colorectal cancer management remains unclear...
Source: Clinical Lung Cancer - August 11, 2022 Category: Cancer & Oncology Authors: Koichi Taira Shunsuke Okazaki Kohei Akiyoshi Hirohisa Machida Tetsuro Ikeya Akie Kimura Akinobu Nakata Yuji Nadatani Masaki Ohminami Shusei Fukunaga Koji Otani Shuhei Hosomi Fumio Tanaka Noriko Kamata Yasuaki Nagami Yasuhiro Fujiwara Source Type: research
Impact of cancer diagnosis on distribution and trends of cardiovascular hospitalizations in the USA between 2004 to 2017
CONCLUSIONS: In contrast to declining trends in patients without cancer, primary cardiovascular admissions in patients with cancer is increasing. The highest admission rates are in patients with hematological cancer and the most common cause of admission is heart failure.PMID:35913736 | DOI:10.1093/ehjqcco/qcac045
Source: Clinical Lung Cancer - August 1, 2022 Category: Cancer & Oncology Authors: Ofer Kobo Zahra Raisi-Estabragh Sofie Gevaert Jamal S Rana Harriette G C Van Spall Ariel Roguin Steffen E Petersen Bonnie Ky Mamas A Mamas Source Type: research
Impact of Comorbidities on Lung Cancer Screening Evaluation
CONCLUSION: Patient and procedure-level factors may alter the benefits of lung cancer screening. Data concerning individual risk factors and high-risk complications should therefore be incorporated into diagnostic algorithms to optimize clinical benefit and minimize harm. Further study and validation of the risk factors identified herein are warranted.PMID:35641376 | DOI:10.1016/j.cllc.2022.03.012
Source: Clinical Lung Cancer - May 31, 2022 Category: Cancer & Oncology Authors: Eric M Robinson Benjamin Y Liu Keith Sigel Chung Yin Juan Wisnivesky Minal S Kale Source Type: research
